Biological significance of DNA adducts: Summary of discussion of expert panel

Regulatory Toxicology and Pharmacology

Volumn 39, Issue 3, 2004, Pages 403-408

  Pottenger, L H ^a,b   Penman, M ^c   Moore, N P ^a,d   Priston, R A J ^e   Thomas, M ^f  

^a DOW EUROPE GMBH   (Switzerland)

^b DOW CHEMICAL COMPANY   (United States)

^c ExxonMobil Biomedical Sciences   (Belgium)

^d BP EXPLORATION   (United Kingdom)

^e Shell Chemicals Ltd   (United Kingdom)

^f Lyondell Chemical Europe Inc   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; MUTANT PROTEIN;

ANALYTIC METHOD; BIOASSAY; CELL ASSAY; CONFERENCE PAPER; DNA ADDUCT; DNA DETERMINATION; HUMAN; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

ANIMALS; CARCINOGENS; DNA ADDUCTS; GERM CELLS; HEALTH; HUMANS; MUTAGENS; MUTATION; RISK ASSESSMENT;

EID: 2342473887     PISSN: 02732300     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yrtph.2004.01.003     Document Type: Conference Paper

References (15)

1. Albertini, R.J., Hayes, R.B., 1997. Somatic cell mutation in cancer epidemiology. IARC Scientific Publications, No 142, International Agency for Research on Cancer, pp. 159-184
2. Barbin A., Laib R.J., Bartsch H. Lack of miscoding properties of 7-(2-oxoethyl)guanine, the major vinyl chloride DNA adduct. Cancer Res. 45:1985;2440-2444
3. Beranek D.T. Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. Mutat. Res. 231:1990;11-30
4. Li F., Segal A., Solomon J. In vitro reaction of ethylene oxide with DNA and characterization of DNA adducts. Chem. Biol. Interact. 83:1992;35-54
5. Maisch M., Vock E.H., Preisler V., Hoppe F., Vamvakas S., Helms J., Lutz W.K. Biomonitoring of DNA adducts in lymphocytes and normal mucosa of pharynx and larynx in cancer patients as potential indicators of smoking dose, duration or age at tumor manifestation. Naunyn Schmiedebergs Arch. Pharmacol. Suppl. 361:2000;R170
6. Otteneder M., Lutz W.K. Correlation of DNA adduct levels with tumor incidence: carcinogenic potency of DNA adducts. Mutat. Res. 424:1999;237-247
7. Phillips D.H., Farmer P.B., Beland F.A., Nath R.G., Poirier M.C., Reddy M.V., Turteltaub K.W. Methods of DNA adduct determination and their application to testing compounds for genotoxicity. Environ. Mol. Mutagen. 35:2000;222-233
8. Poirier M.C., Beland F.A. DNA adduct measurements and tumor incidence during chronic carcinogen exposure in animal models: implications for DNA adduct-based human cancer risk assessment. Chem. Res. Toxicol. 5:1992;749-755
9. Qian G.S., Ross R.K., Yu M.C., Yuan J.M., Gao Y.T., Henderson B.E., Wogan G.N., Groopman J.D. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol. Biomarkers. Prev. 3:1994;3-10
10. Safhill R., Margison G.P., O'Connor P.J. Mechanisms of carcinogenesis induced by alkylating agents. Biochim. Biophys. Acta. 823:1985;111-145
11. Singer B. N -Nitroso alkylating agents: formation and persistence of alkyl derivatives in mammalian nucleic acid as contributing factors in carcinogenesis J. Natl. Cancer Inst. 62:1979;1329-1339
12. Singer B., Grunberger D. Molecular Biology of Mutagens and Carcinogens. 1983;Plenum Press, New York
13. Turteltaub K.W., Felton J.S., Gledhill B.L., Vogel J.S., Southon J.R., Caffee M.W., Finkel R.C., Nelson D.E., Proctor I.D., Davis J.C. Accelerator mass spectrometry in biological dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proc. Natl. Acad. Sci. USA. 87:1990;5288-5292
14. Walker V.E., Fennell T.R., Upton P.B., MacNeela J.P., Skopek T.R., Shuker D.E.G., Swenberg J.A. Molecular dosimetry of ethylene oxide: formation and persistence of 7-(2-hydroxyethyl)guanine in DNA following repeated exposures of rats and mice. Cancer Res. 52:1992;4328-4334
15. Wiencke J.K. DNA adduct burden and tobacco carcinogenesis. Oncogene. 21:2002;7376-7391